Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-037847
Filing Date
2023-11-08
Accepted
2023-11-08 16:12:06
Documents
76
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bcrx-20230930.htm   iXBRL 10-Q 1446966
2 EX-10.2 exhibit102-inducementequit.htm EX-10.2 87185
3 EX-31.1 bcrx-20230930xexx311.htm EX-31.1 9587
4 EX-31.2 bcrx-20230930xexx312.htm EX-31.2 9561
5 EX-32.1 bcrx-20230930xexx321.htm EX-32.1 4633
6 EX-32.2 bcrx-20230930xexx322.htm EX-32.2 4607
  Complete submission text file 0001628280-23-037847.txt   7850107

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20230930.xsd EX-101.SCH 63816
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcrx-20230930_cal.xml EX-101.CAL 53489
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20230930_def.xml EX-101.DEF 273200
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20230930_lab.xml EX-101.LAB 754445
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20230930_pre.xml EX-101.PRE 470154
70 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20230930_htm.xml XML 1072309
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 231387970
SIC: 2836 Biological Products, (No Diagnostic Substances)